Find a Doctor

Zev A. Wainberg

The Regents Of The University Of California
Hematology, Oncology, Internal Medicine
Male
Practicing approx. 21 years

Bio


Zev Wainberg is a Hematologist and an Oncologist in Santa Monica, California. He has been an author on 106 peer reviewed articles and participated in 9 clinical trials in the past 15 years. He is licensed to treat patients in CA.

Contact

Santa Monica, CA 90404, US

Latest Research


Latest Advance
Study
  • Condition: Pancreatic Cancer
  • Journal: BMC cancer
  • Treatment Used: 5-FU and Oxaliplatin-based Therapies
  • Number of Patients: 454
  • Published —
The study researched treatment of pancreatic cancer.
Latest Advance
Study
  • Condition: Advanced-stage Gastroesophageal Junction Adenocarcinoma (GEA)
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Bemarituzumab
  • Number of Patients: 79
  • Published —
The aim of the study was to understand the safety and effectiveness of bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA).
Latest Advance
Study
  • Condition: Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Durvalumab and Tremelimumab Alone or in Combination
  • Number of Patients: 113
  • Published —
The study researched the outcomes of Durvalumab and Tremelimumab alone or in combination for advanced gastric and gastroesophageal junction adenocarcinoma.
Latest Advance
Study
  • Condition: Solid Tumors
  • Journal: British journal of cancer
  • Treatment Used: CFI-400945
  • Number of Patients: 43
  • Published —
In this study, researchers evaluated the safety of CFI-400945 for the treatment of advanced solid tumors.
Latest Advance
Study
  • Condition: Advanced Gastric Or Gastroesophageal Junction Cancer
  • Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • Treatment Used: Pembrolizumab Alone Versus in Combination with Chemotherapy
  • Number of Patients: 56
  • Published —
In this study, researchers compared the effectiveness of pembrolizumab alone versus in combination with chemotherapy for the treatment of advanced gastric or gastroesophageal junction cancer.
Latest Advance
Study
  • Condition: Metastatic Gastric or Gastro-esophageal Junctional Adenocarcinoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Ramucirumab with Cisplatin and Fluoropyrimidine
  • Number of Patients: 645
  • Published —
This study evaluated whether adding ramucirumab to first-line chemotherapy (first treatment given for a disease) with cisplatin and fluoropyrimidine improves the outcomes in patients with metastatic gastric or gastro-esophageal junction adenocarcinoma (cancer of the lower part of the esophagus).
Latest Advance
Study
  • Condition: Locally advanced or metastatic gastric (stomach) or gastroesophageal junction cancer
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: mFOLFOX6 with or without the Akt inhibitor ipatasertib
  • Number of Patients: 153
  • Published —
The study researched the outcomes of mFOLFOX6 with or without the Akt inhibitor ipatasertib in treating locally advanced or metastatic gastric or gastroesophageal junction cancer.
Latest Advance
Study
  • Condition: Advanced Gastroesophageal Adenocarcinomas
  • Journal: The oncologist
  • Treatment Used: FOLFIRI in Combination with Ramucirumab (RAM)
  • Number of Patients: 29
  • Published —
This study evaluated the effectiveness/safety data in gastroesophageal adenocarcinoma (stomach and esophageal cancer; GEA) for FOLFIRI-ramucirumab (ram).

Clinical Trials


Clinical Trial
  • Status: Recruiting
  • Phase: Early Phase 1
  • Intervention Type: Drug
  • Participants: 145
  • Start Date: February 20, 2020
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug, Biological
  • Participants: 111
  • Start Date: January 23, 2020
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 80
  • Start Date: September 24, 2019
A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug, Biological, Procedure
  • Participants: 36
  • Start Date: July 24, 2019
A Pilot and Feasibility Study of PD-1 Blockade With Nivolumab in Combination With Chemotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 376
  • Start Date: August 28, 2017
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 203
  • Start Date: October 3, 2016
A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 48
  • Start Date: March 2014
An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Advanced Cancer

All Publications
View All


Publication
Study
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Published —
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
Publication
Study
  • Journal: The Lancet. Oncology
  • Published —
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply.

Contact

Santa Monica, CA 90404, US

Affiliations

  • Ronald Reagan U C L A Medical Center
  • Santa Monica - Ucla Med Ctr & Orthopaedic Hospital

Credentials

  • Licenses
    Internal Medicine in CA
  • Board Certifications
    Hematology/oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.